Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the blt model for evaluation of new microbicide candidates

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Denton, P. W.
  • Othieno, F.
  • Martinez-Torres, F.
  • Zou, W.
  • Krisko, J. F.
  • Fleming, E.
  • Zein, S.
  • Powell, D. A.
  • Wahl, A.
  • Kwak, Y. T.
  • Welch, B. D.
  • Kay, M. S.
  • Payne, D. A.
  • Gallay, Philippe
  • Appella, E.
  • Estes, J. D.
  • Lu, M.
  • Garcia, J. V.

publication date

  • August 2011

journal

  • Journal of Virology  Journal

abstract

  • Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal HIV transmission in humans. Similarly, we have previously demonstrated that systemic administration of the same FTC-TDF combination efficiently prevented rectal transmission in humanized bone marrow/liver/thymus (BLT) mice. The CAPRISA 004 trial recently demonstrated that topical application of the tenofovir could partially prevent vaginal HIV-1 transmission in humans. To further validate the usefulness of the BLT mouse model for testing HIV prevention strategies, we evaluated the topical administration of tenofovir as used in CAPRISA 004 to prevent vaginal HIV transmission in BLT mice. Our results demonstrate that vaginally administered 1% tenofovir significantly reduced HIV transmission in BLT mice (P = 0.002). Together with the results obtained after systemic antiretroviral PrEP, these topical inhibitor data serve to validate the use of humanized BLT mice to evaluate both systemic and topical inhibitors of HIV transmission. Based on these observations, we tested six additional microbicide candidates for their ability to prevent vaginal HIV transmission: a C-peptide fusion inhibitor (C52L), a membrane-disrupting amphipathic peptide inhibitor (C5A), a trimeric d-peptide fusion inhibitor (PIE12-Trimer), a combination of reverse transcriptase inhibitors (FTC-TDF), a thioester zinc finger inhibitor (TC247), and a small-molecule Rac inhibitor (NSC23766). No protection was seen with the Rac inhibitor NSC23766. The thioester compound TC247 offered partial protection. Significant protection was afforded by FTC-TDF, and complete protection was offered by three different peptide inhibitors tested. Our results demonstrate that these effective topical inhibitors have excellent potential to prevent vaginal HIV transmission in humans.

subject areas

  • Adenine
  • Administration, Topical
  • Animals
  • Base Sequence
  • CD4-Positive T-Lymphocytes
  • Chimera
  • DNA Primers
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Female
  • HIV Infections
  • Humans
  • Mice
  • Organophosphonates
  • Receptors, CCR5
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Vagina
scroll to property group menus

Identity

PubMed Central ID

  • PMC3147928

International Standard Serial Number (ISSN)

  • 0022-538X

Digital Object Identifier (DOI)

  • 10.1128/jvi.00537-11

PubMed ID

  • 21593172
scroll to property group menus

Additional Document Info

start page

  • 7582

end page

  • 7593

volume

  • 85

issue

  • 15

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support